Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.80 |
| ▸ | ACE | P12821 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9068900 | 1.00 | MME (0.80) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL7280386 | 1.00 | MME (0.80) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL7273423 | 1.00 | MME (0.80) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL3631586 | 0.99 | MME (0.82) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL7271591 | 0.94 | MME (0.84) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL7281509 | 0.89 | MME (0.71) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL389731 | 0.89 | MME (1.00) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL29494162 | 0.89 | MME (1.00) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL3623644 | 0.85 | MME (0.68) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL3623638 | 0.85 | MME (0.72) | MMEACEALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-02-25 | — | — | US | claimed |
| EP-3763373-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| CN-110237071-A | Pharmaceutical preparation and its application | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| CN-109803657-A | Pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-05-24 | — | — | CN | claimed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12503426-B2 | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | LIPOVEXA SRL (IT) | 2025-12-23 | — | — | US | disclosed |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| WO-1992013564-A1 | COMBINATION OF AN ANGIOTENSIN II ANTAGONIST OR RENIN INHIBITOR WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR | SCHERING CORPORATION (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0498361-A2 | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor | SCHERING CORPORATION (US) | 1992-08-12 | — | — | EP | disclosed |
| US-4798904-A | ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1989-01-17 | — | — | US | disclosed |
| US-4774256-A | MERCAPTO AND ACYLMERCAPTO AMIDES | E. R. SQUIBB & SONS, INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4722810-A | Enkephalinase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0136883-B1 | ENKEPHALINASE INHIBITORS | E.R. Squibb & Sons, Inc. (US) | 1987-11-25 | — | — | EP | disclosed |
| EP-0136883-A2 | Enkephalinase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503426-B2 | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | GPR119, GLP1R, LPAR1 | MME 2417/4885ACE 3794/4885ALDH1A1 4303/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | MME 3053/4885ACE 1457/4885ALDH1A1 1500/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | MME 1302/4885ACE 1313/4885ALDH1A1 1260/4885 |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | MME 1/4885ACE 4/4885ALDH1A1 3055/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MME 1/4885ACE 4/4885ALDH1A1 3055/4885 |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | MME 1/4885ACE 32/4885ALDH1A1 2416/4885 |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | PREP, PEPD, FURIN | MME 4/4885ACE 152/4885ALDH1A1 1034/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885ALDH1A1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.